ANNUAL REPORT 2025

The world's largest organization dedicated to fighting ovarian & gynecologic cancer









RESEARCH · ADVOCACY · SUPPORT

Ovarian Cancer Research Alliance



Dear Friends,

2025 was a defining year for Ovarian Cancer Research Alliance (OCRA)—a year in which we expanded our reach, strengthened our capabilities, and laid the groundwork for a new era of scientific discovery and patient-centered progress.

We welcomed The Clearity Foundation and the Rivkin Center for Ovarian Cancer Research into OCRA, bringing together exceptional expertise and resources to advance our shared mission. We also invested nearly $10.3 million in research initiatives, part of a $14.5 million commitment to research, patient support, education, and advocacy.

One of our most ambitious undertakings was the development of OCRA's Research Exchange, a new research ecosystem designed to connect patients, researchers, data, and advanced technology in ways that can accelerate discovery. Throughout 2025, we worked to build its infrastructure, including the Living Lab Registry. The Research Exchange represents an important shift in how we approach research: not simply funding promising science but helping create the conditions for discoveries that might otherwise take years longer—or never happen at all.

The impact of sustained research investment was also evident this year. In May, the FDA approved the first treatment for recurrent KRAS-mutated low-grade serous ovarian cancer, building on the work of a scientist whose early research OCRA helped fund. OCRA-funded researchers also developed an AI tool to help predict treatment response. And through our new Global Ovarian Cancer Research Consortium, established with partners in Australia, Canada, and the United Kingdom, we awarded our first $1 million AI Accelerator Grant, bringing international collaboration and advanced technology together to tackle some of the most challenging questions in ovarian cancer research.

At the same time, more people than ever turned to OCRA for information, guidance, and support. Our Patient Support Line received more than 4,200 calls, a 68% increase over the previous year. Participation in Steps 1:1 Counseling more than doubled, and we expanded the program to serve people affected by all gynecologic cancers. Our International Gynecologic Cancer Conference was offered free of charge for the first time, reaching participants in more than 60 countries.

We continued working to close critical gaps in prevention and care. More than 10,000 people have now qualified for free genetic testing kits through OCRA, and research we co-authored revealed that nearly half of women with ovarian cancer are missing essential genetic testing. Through our new Center for Public Policy, our largest-ever class of Advocate Leaders, and more than 21,000 messages delivered to lawmakers, we strengthened our advocacy for policies that advance research, improve access to care, and better serve people affected by gynecologic cancer.

What connects these efforts is our belief that meaningful progress requires more than advances in any one area. Research, prevention, education, support, and advocacy must work together to improve the lives of people affected by gynecologic cancer. That conviction continues to guide OCRA's evolution and our vision for the future.

None of this would be possible without the extraordinary commitment of our donors, volunteers, advocates, researchers, partners, and the patients and families who inspire our work every day. Thank you for helping us build on what we've achieved and for sharing our determination to change what comes next.

Together, we are changing the future of gynecologic cancer.

Sincerely,

Audra Moran

Audra Moran
President & CEO, Ovarian Cancer Research Alliance

2025
by the numbers

NEARLY
$10.3M
INVESTED IN RESEARCH INITIATIVES IN 2025

$14.5M
COMMITTED TO RESEARCH, SUPPORT, EDUCATION & ADVOCACY

4,235+
CALLS TO OUR PATIENT SUPPORT LINE, UP 68% OVER 2024

95,000+
PEOPLE TURNED TO OCRA FOR GUIDANCE, SUPPORT & CONNECTION

10,000+
PEOPLE HAVE NOW QUALIFIED FOR FREE GENETIC TEST KITS

60+
COUNTRIES JOINED OUR FREE INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE

2,820+
MENTOR MATCHES THROUGH WOMAN TO WOMAN, TO DATE

21,000
MESSAGES DELIVERED TO LAWMAKERS BY OUR ADVOCATES

6,600
NEW ADVOCATES JOINED OUR ADVOCACY NETWORK

160
ADVOCATE LEADERS FROM 43 STATES + DC, REPRESENTING 130 CONGRESSIONAL DISTRICTS, THE MOST SINCE INCEPTION


16,450+
HEALTHCARE PROFESSIONAL STUDENTS REACHED BY SURVIVORS TEACHING STUDENTS


DOUBLED
NEW STEPS 1:1 COUNSELING PROGRAM, INTEGRATED FROM THE CLEARITY FOUNDATION, MORE THAN DOUBLED IN SIZE FROM 2024

As of 2025, OCRA has invested a total of $140 million in ovarian and gynecologic cancer research and helped secure more than $3.8 billion in federal research and education funding.

Research

FUNDING SCIENTIFIC BREAKTHROUGHS & PUSHING RESEARCH FORWARD







Research

As the largest non-government funder of ovarian and related gynecologic cancer research, OCRA moves critical science forward. In 2025, we received a record number of research proposals and furthered our global collaborations and impact.

2025 OCRA-FUNDED RESEARCH HIGHLIGHTS:

- Discovered that blocking a key nutrient while also using immunotherapy could offer a promising new treatment strategy for around half of ovarian clear cell cancers.
- Developed a pioneering AI tool to better predict treatment response, a step toward earlier personalized treatment plans.
- Systematically tested existing therapies to find an effective drug combination that shows promise as a treatment for ovarian cancer.
- Found that among people diagnosed with an early ovarian cancer precursor, older patients and Black patients face worse survival, underscoring the urgent need for more tailored care and treatment strategies.
- Found that mucinous ovarian cancers with specific gene changes were associated with worse survival even at early stages, suggesting genetic testing at diagnosis may help guide care and predict outcomes.





1st

FDA APPROVAL FOR ITS TYPE

A MAJOR BREAKTHROUGH ROOTED IN OCRA FUNDING

In May 2025, the FDA approved avutometinib plus defactinib, the first-ever treatment for recurrent KRAS-mutated low-grade serous ovarian cancer. The trial's clinical lead, Dr. Rachel Grisham, received some of her earliest research funding from OCRA.

IN 2025 WE INVESTED NEARLY

$10.3 million

IN RESEARCH INITIATIVES

OCRA's new grants starting in 2025

COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Support of $300,000 annually for three years, for a total of up to $900,000, is granted to the institution where the recipient conducts the research.

Katherine Chiappinelli, PhD
The George Washington University
Combining epigenetic therapy and multi-antigen-specific T cells to treat ovarian cancer
Grant made possible in part by donations from Ovarian Awareness of Kentucky; Ovarian Cycle Massapequa, in memory of Diane Mahlstadt; Ovarian Fitness Orlando, in memory of Kelly, Carol M., Carol T., Adi, Rose, Judi, Vicky, Terry, Wendy, Adriana, Sherry P, and all Teal Divas and ToTEALly Sisters; and Ovarian Cycle Tampa, in memory of Franci Golman Rudolph and Suzanne Maloney.

Branden Moriarity, PhD
University of Minnesota – Twin Cities
Cytokine armored dual-CAR gamma delta T cells target CD70 and CSPG4 in advanced epithelial ovarian cancer
Grant made possible in part by donations from Benton Clark, honoring Johanna M. Clark; Hope for Heather, in memory of Heather Weeks; and Team MB Hunt for the Cure, honoring Maribeth Tobolski.

COLLABORATIVE RESEARCH DEVELOPMENT GRANT IN PARTNERSHIP WITH MICROSOFT'S AI FOR GOOD LAB

Support of $300,000 annually for three years, for a total of up to $900,000, in addition to in-kind Azure compute credits, is granted to the institution where the recipient conducts the research.

Zoltan Szallasi, MD
Boston Children's Hospital
Machine learning based approaches to predict and overcome treatment resistance in ovarian cancer
Grant made possible in part by donations from Hope for Heather, in memory of Heather Weeks, and Judy and Phil Messing, in memory of Carol S. Messing.

EARLY CAREER INVESTIGATOR GRANT

Support of $150,000 annually for three years, for a total of up to $450,000, is granted to the institution where the recipient conducts the research.

Erin George, MD
H. Lee Moffitt Cancer Center & Research Institute
Evolutionarily informed therapies in recurrent ovarian cancer
Grant made possible in part by generous donations in loving memory of Jennifer Lee, and by The Wasily Family Foundation.

Rachael Turner, MD, PhD
University of Rochester
HE4 directed immunotherapy resistance in epithelial ovarian cancer

Yinu Wang, PhD
*Houston Methodist Research Institute**
Redox balance regulates stemness-associated gene transcription in ovarian cancer
Grant made possible in part by a generous donation from the estate of Shirley Johnson.

**Grant initially made to Northwestern University*

John Krais, PhD
Washington University in St. Louis
Targeting RNF168-amplified ovarian cancer
Grant made possible in part by a generous donation from The Melitta S. and Joan M. Pick Charitable Trust.

Yemin Wang, PhD
University of British Columbia
Investigating the role of SMARCA4/2 loss in undifferentiated ovarian cancer using novel mouse models
Grant made possible in part by a donation from Hope for Heather, in memory of Heather Weeks.

HEALTH EQUITY RESEARCH GRANT

Support of $100,000 annually for two years, for a total of up to $200,000, is granted to the institution where the recipient conducts the research.

Stephanie Rieder, MD, PhD
University of New Mexico
Advancing equity in cancer clinical trials by addressing precarity in study design

Abigail Zamorano, MD
UTHealth Houston
Identifying and addressing distress and unmet needs of gynecologic cancer caregivers

Caroline Thompson, PhD
University of North Carolina at Chapel Hill
A mixed methods study of diagnostic delay in ovarian and uterine cancer

MENTORED INVESTIGATOR GRANT

Support in total of up to $100,000, to be used over one or two years, is granted to the institution where the recipient conducts the research.

Tibebe Antonios Teklemariam, PhD
Washington University in St. Louis
Targeting an epigenetic enzyme to enhance chemotherapy response in high-grade serous ovarian cancers
Grant made possible by a generous donation in memory of Susan (Simcha) Rudolph.

Junzui Li, PhD
*Houston Methodist Research Institute**
CD74 mediates the interaction between ovarian cancer cells and the high fat metastatic niche
Grant made possible in part by The Donald R. and Esther Simon Foundation.

**Grant initially made to Ana Maria Isac, PhD, Northwestern University*

Nicola Meagher, PhD
The University of Sydney
Equitable access to BRCA testing: an Australian national data linkage study

Cristabelle De Souza, PhD
Stanford University
Targeting SPP1 in the TME as a therapeutic strategy to chemosensitize ovarian tumors
Grant made possible by a generous donation from The Juliet Viola Kniffen Foundation, in memory of Elizabeth Ann Maggio.

Hao Nie, PhD
The University of Texas MD Anderson Cancer Center
Targeting the acidic tumor microenvironment to improve PARP inhibitor efficacy in ovarian cancer
Grant made possible in part by generous donations from George and Paulette Collias, in memory of Matina, Georgiana and Cindy Gatziolis, and by the Mike and Patti Hennessy Foundation.

OTHER RESEARCH INITIATIVES

Global Ovarian Cancer Research Consortium
Launched with partners in Australia, Canada, and the UK, with a $1 million AI Accelerator Grant and $1 million in compute support from Microsoft's AI for Good Lab.

Ovarian Cancer Observatory and Research Data Network at University of British Columbia (UBC)
OCRA funded promising research partnerships and initiatives at UBC to improve ovarian cancer prevention.

Community Accelerated Research Exchange
In 2025, OCRA announced it will soon launch a first-of-its-kind global, AI-powered platform connecting patients, researchers, and clinicians.


AACR Special Conference
OCRA was the underwriting sponsor of Advances in Ovarian Cancer Research.

Advocacy

THE ONLY DEDICATED VOICE FOR THE OVARIAN & GYNECOLOGIC CANCER COMMUNITY ON CAPITOL HILL











Advocacy

OCRA is the only dedicated voice advocating for the ovarian and gynecologic cancer community on Capitol Hill, working with legislators on federal, state, and local levels to advance policies that impact research, prevention, education, and care.

In 2025, OCRA launched its Center for Public Policy, a dedicated hub that brings together our federal and state policy work, grassroots advocacy, and new tools for action, including real-time, state-by-state policy tracking.

Our largest-ever class of Advocate Leaders, 160 members from 43 states and DC, helped carry that work forward. At our strongest Spring Advocacy Day to date, nearly 120 advocates from across the country held 145 meetings with congressional offices, and advocates helped secure major state-level wins for care and affordability.

Since our founding, OCRA has helped secure over $3.8 billion in federal research and education funding.

145
MEETINGS WITH LAWMAKERS AT SPRING ADVOCACY DAY

21,000
MESSAGES DELIVERED TO LAWMAKERS

6,600
NEW ADVOCATES JOINED OUR NETWORK

CLOSING THE GENETIC TESTING GAP

An analysis OCRA co-authored with Komodo Health found that nearly half of women with ovarian cancer miss essential genetic testing, with the steepest gaps among older women and those on public insurance. To help close that gap, OCRA is advocating for expanded Medicare and Medicaid coverage of genetic testing.

SURVIVORS TEACHING STUDENTS®

Bringing lived experience into the classroom to strengthen medical education.


In 2025, 935 volunteers in the United States delivered 448 presentations, reaching 10,100 healthcare professional students. The international team delivered an additional 53 presentations, reaching 6,354 students. Presentations take place in 41 states and in Washington, DC, as well as the UK, Canada, Australia and New Zealand.

Since its inception, the program has reached more than 145,000 students, helping future healthcare providers understand ovarian cancer beyond the textbook.

145,000+
STUDENTS REACHED ALL TIME

935
VOLUNTEERS IN 2025


427
SCHOOLS IN 2025



Support & Education

FREE PROFESSIONAL SUPPORT & RESOURCES FOR THE GYNECOLOGIC CANCER COMMUNITY











Support & Education

OCRA's support programs provide expert guidance and connection for people impacted by gynecologic cancer, while empowering individuals with information about risk and prevention.

LED BY PROFESSIONALS, FREE TO ALL

Led by professional oncology social workers and informed by the needs of our community, these programs meet people where they are—newly diagnosed, supporting a loved one, or navigating life after treatment.

MORE WAYS TO LEARN

OCRA expanded its educational offerings with the launch of Staying Current, monthly roundtables and webinars, foundational workshops, a caregiver bereavement series, Cancer en Español and dedicated sessions for young adults. An expert-led Q&A on endometrial cancer biomarkers drew more than 1,500 registrants.

STEPS 1:1 COUNSELING, MORE THAN DOUBLED

Personalized counseling that came to OCRA through The Clearity Foundation more than doubled in 2025 over the prior year. Through a partnership with Iris by OncoHealth, the program offers licensed oncology social work counseling within the US for any gynecologic cancer.

PREVENTION & RISK

More than 10,000 people have now qualified for free genetic test kits. With BlackDoctor.org, we created videos on genetic testing for Black women, and Fortune featured OCRA's work educating people about opportunistic salpingectomy.

60+ COUNTRIES joined our International Gynecologic Cancer Conference®, free for the first time in 2025 and our best-attended yet.

4,235+

CALLS MADE TO OUR PATIENT SUPPORT LINE

Up 68% over 2024

95,000+

PEOPLE TURNED TO OCRA PROGRAMS AND COMMUNITY FOR GUIDANCE, SUPPORT & CONNECTION

2,820+

MENTOR MATCHES THROUGH OUR WOMAN TO WOMAN PROGRAM, TO DATE

1,540

CLINICAL TRIAL QUESTIONNAIRES COMPLETED THROUGH OUR CLINICAL TRIAL NAVIGATOR

Up 59% over 2024

Growing the OCRA community

THE CLEARITY FOUNDATION

Joined January 2025

Known for personalized, science-based support, including Steps 1:1 Counseling, now part of OCRA's free programs. Founder Laura Shawver, PhD, an OCRA board member, was named a Fierce 50 Leadership Honoree.

RIVKIN CENTER FOR OVARIAN CANCER RESEARCH

Joined April 1, 2025

Carries forward Dr. Saul Rivkin's legacy of funding innovative research, with signature programs including the Ovarian Cancer Research Symposium and SummeRun.





Community in action

Across the country, our community took action to power OCRA's mission. Here is a sampling of 2025 highlights.




900+
PARTICIPANTS

$320K+
RAISED FOR INNOVATIVE RESEARCH

RIVKIN FAMILY SUMMERUN, 32 YEARS STRONG

On July 13, the first SummeRun since the Rivkin Center joined OCRA brought our community together at Seward Park in Seattle.







OVARIAN CYCLE & OVARIAN FITNESS

Events took place in Houston, Orlando, Tampa, Virginia Beach, Massapequa, Washington, DC, and Rio Grande Valley, which marked its 10th anniversary.

SEPTEMBER CAMPAIGN

During Ovarian & Gynecologic Cancer Awareness Month, supporters shared OCRA's educational graphics on social media to raise awareness of risk, prevention, symptoms and more.

WRAPPED IN LOVE × KELLY RIPA

For Ovarian Cancer Awareness Month, Kelly Ripa and Wrapped in Love released limited-edition teal socks, with 100% of every sale donated to OCRA.

YEAR-END GIVING

A generous board member matched gifts dollar for dollar up to $500,000, and together we reached our $2 million year-end campaign goal.

DIY FUNDRAISERS

Supporters got creative to raise funds for OCRA's programs, from racing up the Empire State Building to donating proceeds from book sales.

IN THE NEWS

OCRA's work reached audiences through Fortune, NBC News Radio, FOX 5 DC, WUSA-TV, KVIA-TV ABC-7, and more.

A sampling of 2025 community events and highlights; not a complete list.

Board of Directors

as of November 2026

EXECUTIVE COMMITTEE

John Orrico	*Chair*
Matthew Neal Miller	*Vice President*
Robin S. Cohen	*Secretary*
Mark Tessar, CPA, CIA	*Treasurer*
Thomas C. Liebman	*At-Large*

BOARD MEMBERS

Debra Birnbaum

Jeannette Chang

Mei-Li da Silva Vint, Esq.

Andrew Feuerstein, Esq.

Carol J. Hamilton

John W. Hansbury, Esq.*

Caroline Hirsch

Dana L. Mark, Esq.*

Melissa Rivkin

Lisa Schreiber

Laura Shawver, PhD

Chris Tilberis

**Emeritus Executive Committee Member*

Scientific Advisory Committee

as of November 2026

Ronald D. Alvarez, MD, MBA, Chair (2016–present)
Vanderbilt University Medical Center

Deborah K. Armstrong, MD (2016–present)
Johns Hopkins School of Medicine

Robert C. Bast, Jr., MD (1997–present)
MD Anderson Cancer Center

Andrew Berchuck, MD (2000–present)
Duke Comprehensive Cancer Center

Jonathan S. Berek, MD, MMS (1997–present)
Stanford University School of Medicine

Benjamin Bitler, PhD (2025–present)
University of Colorado Anschutz Medical Campus

Molly Brewer, DVM, MD, MS (2004–present)
University of Washington Seattle

Ronald Buckanovich, MD, PhD (2013–present)
Magee-Womens Research Institute

Jeremy Chien, PhD (2025–present)
University of California, Davis School of Medicine

Kathleen Cho, MD (2022–present)
University of Michigan Medical School

Robert L. Coleman, MD (2016–present)
Vaniam Group

Jose Conejo-Garcia, MD, PhD (2025–present)
Duke University

Oliver Dorigo, MD, PhD (2023–present)
Stanford University

Katherine Fuh, MD, PhD (2021–present)
University of California, San Francisco

Gillian E. Hanley, PhD (2022–present)
University of British Columbia

Gwen Harding-Peets, PhD (2024–present)
Patient Advocate

David Huntsman, MD, FRCPC, FCCMG (2024–present)
University of British Columbia

Beth Y. Karlan, MD (2019–present)
UCLA Medical Center

Dineo Khabele, MD (2015–present)
Washington University School of Medicine

Daniela Matei, MD (2025–present)
Houston Methodist

Ursula Matulonis, MD, Grants Oversight Chair (2014–present)
Dana-Farber Cancer Institute

Kathleen Moore, MD, MS (2021–present)
University of Nebraska

Kenneth Nephew, PhD (2014–present)
Indiana University

Sandra Orsulic, PhD (2011–present)
David Geffen School of Medicine at UCLA

Leigh Pearce, PhD, MPH (2015–present)
University of Michigan

Carolyn D. Runowicz, MD (1997–present)
Florida International University

Sohrab Shah, PhD (2025–present)
Memorial Sloan Kettering Cancer Center

Ie-Ming Shih, MD, PhD (2013–present)
Johns Hopkins University School of Medicine

Anil K. Sood, MD (2016–present)
MD Anderson Cancer Center

Kathryn Terry, ScD (2025–present)
Brigham and Women's Hospital and Harvard Medical School

Shelley Tworoger, PhD (2019–present)
Oregon Health & Science University

Jason D. Wright, MD (2021–present)
Tufts Medical Center

Staff

as of November 2026

Audra Moran
President & CEO

Sarah Assarsson, LICSW
Steps Counselor

Lindsay Bernier
Development Coordinator

Anne Mette Buhl, PhD
Senior Director, Treatment Access & Scientific Education

Erin Cassin
Associate Director, Social Media & Content

Nancy Cincotta, LCSW, MPhil
Senior Director, Social Work Education & Research

Jenny Daugherty
Associate Manager, Development

Sarah DeFeo
Chief Program Officer

Sarah Handsman, LCSW, OSW-C
Director, Patient Support

Jackie Lang, PhD
Director, Scientific Programs

Susan Leighton
Director, Survivors Teaching Students

Liza Lundgren, LCSW
Director, Education

Diana Maynard
Director, Events

Kristin McGowan
Senior Director, Grants & Scientific Affairs

Tracy Moore, LCSW
Vice President, Support & Education

Josephine Neil
Manager, Operations & Finance

Kimberly Nelson, MSW, LCSW, OSW-C
Steps Counselor

Shirley Pattan, LCSW, LICSW
Steps Counselor

Brian Phair
Senior Director, Donor Relations

Emily Rakos
Manager, Programs

Allison Ramiller
Senior Director, Living Lab Registry

Chad Ramsey
Vice President, Policy

Debbie Robins
Senior Director, Strategic Alliances

Jahnessa Ryea
Manager, Policy

Lydia Smith
Vice President, Operations & Finance

Sara Stoffmacher, LMSW
Senior Manager, Patient Support

Julia Thayer
Associate Director, Advocacy

Matthew Trunnell
Principal Architect, Research Exchange

Nikki Wargo
Chief of Staff and Vice President, Philanthropic Partnerships

Lindsey Weeks
Senior Director, Strategic Communications

Jon Zeidman
Chief Development Officer

Financial statement

	2025	2024
Total Revenue & Support	**$19,362,039**	**$12,468,752**
Expenses		
Program Services		
Research	$10,293,100	$7,048,631
Advocacy	$595,806	–
Education and Support	$3,631,886	–
Total Program Services	**$14,520,792**	**$10,245,977**
Fundraising	$2,073,821	$1,425,591
Administrative	$1,089,742	$1,199,427
Total Expenses	**$17,684,355**	**$12,870,995**
Ending Net Assets	**$27,052,625**	**$23,155,821**

2024 reported program spending as Research, Conference ($982,758) and Education, Support and Advocacy ($2,214,588), so Advocacy and Education and Support have no 2024 comparison.


82%

OF EXPENSES WENT DIRECTLY TO PROGRAMS



Programs · Fundraising · Admin: 82% · 12% · 6%

REVENUE BREAKDOWN



**Including Conference · **Donated Services & Other Revenue*